ArticleClinical optometry2026
The Meibomian Gland Composite Score (MGCS): A Novel Grading System Integrating Existing Scales for Meibomian Gland Dysfunction.
Article in Clinical optometry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To introduce and evaluate the clinical performance of the Meibomian Gland Composite Score (MGCS), a novel, standardized, video- and pictorial-based grading system designed to provide a linear, gland-specific assessment of meibomian gland dysfunction (MGD) severity. Methods: The MGCS evaluates meibum quality on a 0 to 4 scale based on texture and expressibility across the central 8 upper eyelid glands (score 0-32) and central 5 lower eyelid glands (score 0-20). To evaluate clinical performance, two independent providers performed a retrospective chart review of 53 patients (mean age 60.9 ± 16.4 years; 75.5% female). Receiver operating characteristic (ROC) curves were generated using tear breakup time (TBUT ≤5 seconds) as the reference standard for evaporative dry eye disease (DED) to determine optimal diagnostic cut points. Results: The MGCS demonstrated strong diagnostic accuracy for evaporative DED, with area under the curve (AUC) values of 0.9539 (right upper eyelid), 0.9182 (right lower eyelid), 0.9105 (left upper eyelid), and 0.7779 (left lower eyelid). An MGCS score ≥10 for an individual eyelid provided optimal diagnostic balance (sensitivity up to 93.75%, specificity up to 85.71%) for identifying abnormal gland function. Conclusion: The MGCS offers a standardized and continuous scale for assessing MGD severity. By incorporating detailed meibum texture descriptions supported by standardized pictorial and video references, the scale facilitates precise disease tracking and robust statistical analysis in both clinical practice and research settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.